Research program member: Cancer Molecular Genetics
1101 E. Marshall St.
Richmond, VA 23298
Assistant Professor, Obstetrics and Gynecology, School of Medicine
PhD, University of Cincinnati (2002)
The best defense against cancer development and treatment is giving a patient their own immune cells. However, current immunotherapy is inadequate and causes other health issues, mainly due to immune cells attacking both the cancer and host cells. So far, there is no current method to improve tumor-specific targeting strategy without harming the host cells. Interestingly, our preliminary data strongly suggests that ERAP2(N) protein in the solid tumor can flag a strong signal to host immune cells to specifically eliminate the cancer cells without harming the neighboring non-cancer cells. Unfortunately, we do not clearly understand how this protein helps immune cells to eliminate only the tumor cells. Therefore, the ultimate goal of the proposed research program is to understand how ERAP2(N) improves tumor targeting and elimination to provide efficacy of such a potential treatment. To reach this goal, our group has established an ERAP2(N) tumor mouse model to evaluate what other proteins are involved with ERAP2(N) to recruit immune cells during tumor targeting. The main goal for this proposal is to determine and identify protein alteration elicited by ERAP2 in tumor/immune microenvironment.
Angiogenesis,Animal models,Cancer cell biology,Immunotherapy,Targeted therapies,Translational science,Tumor microenvironment